Bohui Innovation: Controlled subsidiary receives approval for clinical trials of intravenous immunoglobulin

Bohui Innovation announced that its holding subsidiary Guangdong Weilun's application for intravenous immunoglobulin has been approved by the National Medical Products Administration for clinical trials. The drug acceptance number is CXSL2500861, and it is indicated for primary/secondary immunoglobulin deficiency diseases, autoimmune diseases, etc. After approval, clinical studies must be conducted as required and approved before the drug can be marketed. However, drug development carries high risks and a long cycle. The approval at this stage is a partial achievement and will not have a significant impact on the company's recent performance.